Universität zu Köln

Hoemberg, Marc, Schwenzfeur, Ruth, Berthold, Frank ORCID: 0000-0002-7613-1723, Simon, Thorsten ORCID: 0000-0002-3425-8451 and Hero, Barbara (2022). Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastoma. Pediatr. Blood Cancer, 69 (2). HOBOKEN: WILEY. ISSN 1545-5017

Full text not available from this repository.

Abstract

Purpose 13-cis-Retinoic acid (13-cisRA) is used as a postconsolidation treatment in patients with high-risk neuroblastoma. Hypercalcemia is a known side effect of retinoids. Frequency, symptoms, treatment, and risk factors for hypercalcemia were analyzed. Patients Data were retrospectively analyzed for 350 patients registered in the German Neuroblastoma trials NB97 and NB04 who were treated with high-risk protocols-including myeloablative chemotherapy with autologous stem cell transplantation (SCT) or maintenance therapy-and had received 13-cisRA between January 1, 2000 and December 31, 2010. Results Hypercalcemia was reported in 78 patients (22.3%), and 37 patients (10.6%) developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 hypercalcemia. The calcium levels were 2.5-4.6 mmol/L (median 3.1 mmol/L). Patients with a single kidney were at a higher risk of developing hypercalcemia (p = .001). Regarding postinduction treatment, 69 of 280 patients with SCT (24.6%) and nine of 70 patients without SCT (12.9%) developed hypercalcemia during 13-cisRA treatment (p = .037). Most patients developed hypercalcemia in the first cycle of 13-cisRA, and only in a single cycle. Hypercalcemia symptoms were frequent but moderate. In most patients, treatment with 13-cisRA was continued without dose reduction in subsequent cycles. Conclusion In this cohort, grades 3 and 4 hypercalcemia were observed more often than previously reported. A single kidney and pretreatment with myeloablative chemotherapy with stem cell transplantation were identified as potential risk factors for the development of hypercalcemia.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hoemberg, Marc UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwenzfeur, Ruth UNSPECIFIED UNSPECIFIED UNSPECIFIED Berthold, Frank UNSPECIFIED orcid.org/0000-0002-7613-1723 UNSPECIFIED Simon, Thorsten UNSPECIFIED orcid.org/0000-0002-3425-8451 UNSPECIFIED Hero, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-563033
DOI:	10.1002/pbc.29374
Journal or Publication Title:	Pediatr. Blood Cancer
Volume:	69
Number:	2
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1545-5017
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; HIGH-DOSE CHEMOTHERAPY; VITAMIN-D-RECEPTOR; STEM-CELL RESCUE; X-RECEPTOR; RANDOMIZED-TRIAL; CHILDREN; THERAPY; ISOTRETINOIN Multiple languages Oncology; Hematology; Pediatrics Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/56303